Hover Automotive India appoints Dinesh Jain as CEO

In its quest to bring the finest talent on board, Nissan Motor India Pvt Ltd's has appointed Dinesh Jain as the chief executive officer (CEO) of its alliance partner Hover Automotive India.

Hover Automotive India is a strategic alliance partner for Nissan Motor India in handling sales, marketing and customer relationship management of Nissan in India.

"We welcome Dinesh Jain to our extended organisation and look forward to his vast knowledge and expertise in enabling us to create a strong brand equity for Nissan in India," Nissan Motor India managing director and CEO Kiminobu Tokuyama said in a company statement.

Mr Jain, an MBA graduate in marketing, was earlier serving as the CEO of Zee Turner Group. He has over 24 years of experience in high growth FMCG and media companies, according to the company release.
 

User

Zensar to buy US-based PSI Holdings Group

IT firm Zensar Technologies Ltd said it has entered an agreement to acquire a US-based limited liability company PSI Holdings Group Inc and its subsidiary.

The wholly-owned subsidiary of the company, Zensar Technologies, has entered into an agreement to acquire PSI Holdings Group Inc and its wholly-owned subsidiaries, Zensar Technologies said in a Bombay Stock Exchange.

However, the company did not disclose the financial details of the acquisition. 
On Monday, Zensar Technologies ended 2.44% up at Rs161.80 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.90% up at 19,957.59 points.
 

User

Bafna Pharma gets UK nod to make Finasteride tablets

Drug firm Bafna Pharmaceuticals Ltd said it has received approval from UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture Finasteride, used in the treatment of enlarged prostate gland.

The company will manufacture Finasteride in 5mg dosage, Bafna Pharmaceuticals said in a statement.

The approval from UK MHRA for Finasteride 5mg will enable the company to widen the customer base in Europe.

Finasteride 5mg tablet is a prescription-only medicine used for the treatment and control of benign prostatic hyperplasia in order to cause regression of an enlarged prostate and improvement of other symptoms.

On Monday, Bafna Pharma rose 1.59% to Rs47.80 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.90% up at 19,957.59 points.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)